Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Guggenheim Downgrades Rubius Therapeutics to Neutral

Guggenheim Downgrades Rubius Therapeutics to Neutral

Guggenheim analyst Michael Schmidt downgrades Rubius Therapeutics (NASDAQ:RUBY) from Buy to Neutral.

September 13, 2022

1 minute read

Guggenheim analyst Michael Schmidt downgrades Rubius Therapeutics (NASDAQ:RUBY) from Buy to Neutral.

Where Agilent Technologies Stands With Analysts

July 8, 8:40 AM

Analysts have provided the following ratings for Agilent Technologies (NYSE:A) within the last quarter:

August 30, 12:28 PM

Last week, Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) dengue vaccine, Qdenga, was approved in Indonesia for individuals six to 45 years of age.…

September 14, 7:22 AM

Credit Suisse analyst Shannon Cross maintains TD Synnex (NYSE:SNX) with a Neutral and lowers the price target from $115 to $110.

November 1, 12:15 PM

Spirit AeroSystems Holdings, Inc. (NYSE: SPR) reported third-quarter FY23